|
1
|
Petrozza V, Pastore AL, Palleschi G, Tito
C, Porta N, Ricci S, Marigliano C, Costantini M, Simone G, Di Carlo
A, et al: Secreted miR-210-3p as non-invasive biomarker in clear
cell renal cell carcinoma. Oncotarget. 8:69551–69558. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King SC, Pollack LA, Li J, King JB and
Master VA: Continued increase in incidence of renal cell carcinoma,
especially in young patients and high grade disease: United States
2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel C, Ahmed A and Ellsworth P: Renal
cell carcinoma: A reappraisal. Urol Nurs. 32:182–190; quiz 191.
2012.PubMed/NCBI
|
|
7
|
Hadoux J, Vignot S and De La Motte Rouge
T: Renal cell carcinoma: Focus on safety and efficacy of
temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Homami A and Ghazi F: MicroRNAs as
biomarkers associated with bladder cancer. Med J Islamic Repub
Iran. 30:4752016.
|
|
9
|
Enokida H, Yoshino H, Matsushita R and
Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin
Urol. 1 Suppl 57:S60–S76. 2016. View Article : Google Scholar
|
|
10
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding D, Zhang Y, Wen L, Fu J, Bai X, Fan
Y, Lin Y, Dai H, Li Q, Zhang Y, et al: MiR-367 regulates cell
proliferation and metastasis by targeting metastasis-associated
protein 3 (MTA3) in clear-cell renal cell carcinoma. Oncotarget.
8:63084–63095. 2017.PubMed/NCBI
|
|
13
|
Cai W, Jiang H, Yu Y, Xu Y, Zuo W, Wang S
and Su Z: miR−367 regulation of DOC-2/DAB2 interactive
protein promotes proliferation, migration and invasion of
osteosarcoma cells. Biomed Pharmacother. 95:120–128. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan L, Cai K, Liang J, Liu H, Liu Y and
Gui J: Interaction between miR-572 and PPP2R2C, and their effects
on the proliferation, migration, and invasion of nasopharyngeal
carcinoma (NPC) cells. Biochem Cell Biol. 95:578–584. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu AH, Huang YL, Zhang LZ, Tian G, Liao QZ
and Chen SL: MiR-572 prompted cell proliferation of human ovarian
cancer cells by suppressing PPP2R2C expression. Biomed
Pharmacother. 77:92–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Tian H, Yuan J, Wu H, Wu J and Zhu
X: CONSORT: Sam68 is directly regulated by MiR-204 and promotes the
self-renewal potential of breast cancer cells by activating the
wnt/beta-catenin signaling pathway. Medicine. 94:e22282015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hatziapostolou M, Polytarchou C and
Iliopoulos D: miRNAs link metabolic reprogramming to oncogenesis.
Trends Endocrinol Metab. 24:361–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sellitti DF and Doi SQ: MicroRNAs in renal
cell carcinoma. Microrna. 4:26–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dey N, Das F, Ghosh-Choudhury N, Mandal
CC, Parekh DJ, Block K, Kasinath BS, Abboud HE and Choudhury GG:
microRNA-21 governs TORC1 activation in renal cancer cell
proliferation and invasion. PLoS One. 7:e373662012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Zabirnyk O, Wang H, Shiao YH,
Nickerson ML, Khalil S, Anderson LM, Perantoni AO and Phang JM:
miR-23b* targets proline oxidase, a novel tumor suppressor protein
in renal cancer. Oncogene. 29:4914–4924. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Wang C, Li H, Niu X, Liu X, Pei
D, Guo X, Xu X and Li Y: miR-338-3p inhibits the invasion of renal
cell carcinoma by downregulation of ALK5. Oncotarget.
8:64106–64113. 2017.PubMed/NCBI
|
|
28
|
Chen C, Xue S, Zhang J, Chen W, Gong D,
Zheng J, Ma J, Xue W, Chen Y, Zhai W, et al:
DNA-methylation-mediated repression of miR-766-3p promotes cell
proliferation via targeting SF2 expression in renal cell carcinoma.
Int J Cancer. 141:1867–1878. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mundalil Vasu M, Anitha A, Takahashi T,
Thanseem I, Iwata K, Asakawa T and Suzuki K: Fluoxetine increases
the expression of miR-572 and miR-663a in human neuroblastoma cell
lines. PLoS One. 11:e01644252016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu X, Liu S, Li J, Fan X, Chen Y, Bi X,
Liu S and Deng X: MicroRNA-572 improves early post-operative
cognitive dysfunction by down-regulating neural cell adhesion
molecule 1. PLoS One. 10:e01185112015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu
J, Wu G, Li J and Jiang L: Upregulation of miR-572
transcriptionally suppresses SOCS1 and p21 and contributes to human
ovarian cancer progression. Oncotarget. 6:15180–15193.
2015.PubMed/NCBI
|
